Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 3
2006 2
2007 3
2008 3
2009 3
2010 4
2011 3
2013 1
2014 2
2015 1
2016 3
2018 2
2019 2
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Detecting Selection in the HIV-1 Genome during Sexual Transmission Events.
Seifert D, Joos B, Braun DL, Oberle CS, Schenkel CD, Kuster H, Grube C, Böni J, Yerly S, Aubert V, Klimkait T, Günthard HF, Beerenwinkel N, Metzner KJ, On Behalf Of The Swiss Hiv Cohort Study. Seifert D, et al. Among authors: kuster h. Viruses. 2022 Feb 16;14(2):406. doi: 10.3390/v14020406. Viruses. 2022. PMID: 35215999 Free PMC article.
Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.
West E, Zeeb M, Grube C, Kuster H, Wanner K, Scheier T, Neumann K, Jörimann L, Hampel B, Metzner KJ, Kouyos RD, Braun DL, Günthard HF. West E, et al. Among authors: kuster h. Clin Infect Dis. 2023 Oct 5;77(7):1012-1020. doi: 10.1093/cid/ciad366. Clin Infect Dis. 2023. PMID: 37338148 Free PMC article. Clinical Trial.
Determinants of HIV-1 broadly neutralizing antibody induction.
Rusert P, Kouyos RD, Kadelka C, Ebner H, Schanz M, Huber M, Braun DL, Hozé N, Scherrer A, Magnus C, Weber J, Uhr T, Cippa V, Thorball CW, Kuster H, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Fellay J, Regoes RR, Günthard HF, Trkola A; Swiss HIV Cohort Study. Rusert P, et al. Among authors: kuster h. Nat Med. 2016 Nov;22(11):1260-1267. doi: 10.1038/nm.4187. Epub 2016 Sep 26. Nat Med. 2016. PMID: 27668936
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study. Kouyos RD, et al. Among authors: kuster h. Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10. Nature. 2018. PMID: 30202088
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
Kadelka C, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun DL, Huber M, Scherrer AU, Weber J, Uhr T, Kuster H, Misselwitz B, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos RD, Günthard HF, Trkola A; Swiss HIV Cohort Study. Kadelka C, et al. Among authors: kuster h. J Exp Med. 2018 Jun 4;215(6):1589-1608. doi: 10.1084/jem.20180246. Epub 2018 May 24. J Exp Med. 2018. PMID: 29794117 Free PMC article.
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
Moldt B, Parvangada A, Martin R, Pace C, Balakrishnan M, Thomsen ND, E Collins S, Kuster H, Braun DL, Günthard HF, Geleziunas R, Callebaut C. Moldt B, et al. Among authors: kuster h. J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):61-69. doi: 10.1097/QAI.0000000000002722. J Acquir Immune Defic Syndr. 2021. PMID: 34397744
Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.
Jörimann L, Tschumi J, Zeeb M, Leemann C, Schenkel CD, Neumann K, Chaudron SE, Zaheri M, Frischknecht P, Neuner-Jehle N, Kuster H, Braun DL, Grube C, Kouyos R, Metzner KJ, Günthard HF; Swiss HIV Cohort Study (SHCS). Jörimann L, et al. Among authors: kuster h. J Infect Dis. 2023 Oct 3;228(7):907-918. doi: 10.1093/infdis/jiad292. J Infect Dis. 2023. PMID: 37498738 Free PMC article.
41 results